EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer-Reference-Cited by-同舟云学术

EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer

Published:2014-10 Issue:10 Volume:25 Page:1941-1948
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Heymach J.V.,Lockwood S.J.,Herbst R.S.,Johnson B.E.,Ryan A.J.

Funder

Cancer Research UK

AstraZeneca

Medical Research Council

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/10/1941/19546467/mdu269.pdf

Reference35 articles.

1. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration;Wedge;Cancer Res,2002

2. ZD6474—a novel inhibitor of VEGFR and EGFR tyrosine kinase activity;Ryan;Br J Cancer,2005

3. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary;Thornton;Clin Cancer Res,2012

4. Vandetanib for the treatment of thyroid cancer;Langmuir;Clin Pharmacol Ther,2012

5. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial;Herbst;Lancet Oncol,2010

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological approaches for targeting lysosomes to induce ferroptotic cell death in cancer;Cancer Letters;2024-04

2. Current Trends in the Development of EGFR Inhibitors as Promising Anticancer Agents: Sar and Synthetic Studies from (2010-2020);Current Organic Chemistry;2023-01

3. Tumor Angiogenesis;Holland‐Frei Cancer Medicine;2022-10-21

4. Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma;Cancer Discovery;2021-09-22

5. TRPM2-AS promotes cancer cell proliferation through control of TAF15;The International Journal of Biochemistry & Cell Biology;2020-03